RecruitingPhase 1NCT06710158

Study of SC-102 in Patients With Advanced Solid Tumors

Phase Ⅰ Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-102 in Subjects With Advanced or Metastatic Solid Tumors That Express EphA2

Sponsor

Tianjin ConjuStar Biologics Co., Ltd.

Enrollment

120 participants

Start Date

Dec 5, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Cancers

Summary

This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SC-102 for people with advanced solid cancers. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSC-102

SC-102 is a peptide drug conjugate (PDC) consisting an EphA2-targeting peptide, a tubulin inhibitor, and a protease-hydrolyzable linker.

Locations(1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06710158

Related Trials

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

NCT0718684216 locations

ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers

NCT072380759 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor

NCT076128911 location

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

NCT072900884 locations

Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers

NCT074751821 location